Recap of ASCO 2025 for Genitourinary (GI) Cancers

3 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Dr. Joshua K. Sabari sat down with Dr. Daniel V. Araujo to discuss topline takeaways from the 2025 ASCO Annual Meeting across the realm of genitourinary oncology, spanning prostate and bladder cancers. In the interview, the pair covered updates from the AMPLITUDE trial evaluating patients with prostate cancer, as well as discussed the utility of circulating tumor DNA (ctDNA) in muscle-invasive bladder cancer

Sabari is the editor in chief of CURE, as well as the assistant professor in the Department of Medicine at NYU Grossman School of Medicine and director of High Reliability Organization Initiatives at Perlmutter Cancer Center. Araujo serves as a medical oncologist at the University of Florida Health (UF) Health.

The pair began by delving into the AMPLITUDE trial, a randomized controlled trial, investigating the role of Akeega (niraparib plus abiraterone acetate [Zytiga]) versus Zytiga for patients with metastatic hormone-sensitive prostate cancer whose disease has homologous recombination repair (HRR) gene defects.

During a presentation shared at the ASCO Meeting, investigators revealed that with the investigative combination, there was a 37% reduction in the risk of radiographic progression or death compared with the placebo combination in this previously treated patient population. Moreover, the risk symptomatic progression was significantly reduced by 50% with the investigative combination versus placebo. Overall survival data, though not statically significant yet, are also showing trends towards improvement with Akeega.

Also during their conversation, Sabari and Araujo broke down the current role of ctDNA in the genitourinary cancers landscape. ctDNA are small pieces of DNA which can be detected and are released by tumor cells into a person’s blood. If detected early, ctDNA has the potential to guide treatment decisions, and has already displayed a prognostic effect in those with muscle-invasive bladder cancer.

View more at http://curetoday.com/

Or visit our socials!

https://x.com/cure_today
https://www.instagram.com/curetoday/
https://www.facebook.com/curemagazine/
https://www.linkedin.com/company/cure-media-group/

CURE® has become the largest consumer magazine in the United States, focusing entirely on cancer. With a total circulation of 285,000, individual subscribers account for over 140,000 of that figure, with the remainder including cancer centers and advocacy groups around the country. CURE®’s time-tested approach combines science, humanity and technology to make cancer understandable for patients and their caregivers.
Category
Oncology
Be the first to comment

Up Next